Search results
Of the three Salmonella vaccines, the inactivated whole cell vaccine has been the most effective with a three year cumulative efficacy of 73%. 17 The major drawback, and reason why this vaccine is no longer used, 17 is its high level of reactogenicity 90, 91 which, while previously tolerated by military personnel, is unacceptable for general use.
- Salmonella Combination Vaccines: Moving Beyond Typhoid
Typhoid conjugate vaccines are efficacious against...
- Salmonella Combination Vaccines: Moving Beyond Typhoid
The existing Ty21a live-attenuated and Vi capsular polysaccharide vaccines target S. Typhi and are not effective in young children where the burden of invasive Salmonella disease is highest. After years of lack of investment in new Salmonella vaccines, recent times have seen increased interest in the area led by emerging-market manufacturers ...
2 cze 2023 · Typhoid conjugate vaccines are efficacious against Salmonella Typhi. Globally, most Salmonella disease in humans is caused by non-Typhi Salmonella serovars. Nontyphoidal Salmonella and paratyphoid require combination Salmonella vaccines. A quadrivalent Salmonella vaccine could prevent a large majority of Salmonella disease.
In this review we focus on (1) recent advances in live attenuated Salmonella vaccine development, (2) improvements in expression of foreign antigens in carrier vaccines and (3) adaptation of attenuated strains as sources of purified antigens and vesicles that can be used for subunit and conjugate vaccines or together with attenuated vaccine ...
20 kwi 2024 · An effective bivalent vaccine would provide protection against enteric fever caused by Salmonella Typhi and Salmonella Paratyphi A, helping to mitigate increasing antimicrobial resistance. Sii-PTCV was safe and immunogenic in a phase 1 study.
7 maj 2014 · Of the three Salmonella vaccines, the inactivated whole cell vaccine has been the most effective with a three year cumulative efficacy of 73%.
Notably, both total and overall vaccine protection was significant in all vaccinated age groups, including children younger than 2 years, in whom robust anti-Vi IgG responses were also observed. The vaccine was well tolerated, and no serious vaccine-related adverse events were identified.
